US Pharma MarketingThe post Pfizer reports Phase II data for 25vPnC infant vaccine candidate appeared first on Clinical Trials Arena.
Pfizer reports Phase II data for 25vPnC infant vaccine candidate
Pfizer has reported data from a Phase II trial assessing PF-07872412, its investigational 25-valent pneumococcal conjugate vaccine candidate, in infants. The results showed that a four-dose regimen provoked immune responses against all 25 assessed serotypes. The findings support Pfizer’s paediatric Phase III programme, comprising three trials launched to enrol up to 6,830 participants. Credit: SmartPhotoLab / Shutterstock.com. Pfizer has reported findings from a Phase II trial assessing PF-07872412 (25vPnC), its investigational 25-valent pneumococcal conjugate vaccine candidate, in infants. The results showed that a four-dose regimen provoked immune responses against all 25 assessed serotypes. LOA and PTSR Model PVX-2 in…
Pfizer has reported data from a Phase II trial assessing PF-07872412, its investigational 25-valent pneumococcal conjugate vaccine candidate, in infants.
Source: Clinical Trials Arena